Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TauRx Therapeutics Ltd.

http://www.taurx.com/

Latest From TauRx Therapeutics Ltd.

TauRx Attempts Anti-Tau Comeback But Keeps Data Under Wraps

The firm has revealed its anti-tau candidate showed promise in a late-stage Alzheimer’s study several years after a disappointing failure, but data are yet to be announced in full. 

Clinical Trials Companies

Finance Watch: $2.2bn In New Funding Sources In February, So Far

Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.

Financing Innovation

Anti-Tau For Alzheimer's In The Dock After Semorinemab Fail

Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.

Neurology Clinical Trials

Roche Partners With UCB On Anti-Tau Alzheimer’s Drug

UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Other Names / Subsidiaries
    • WisTa Laboratories Ltd.
UsernamePublicRestriction

Register